Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 5/20 | 0.39 |
| ▸ | THRA | P10827 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238955 | 0.97 | PLA2G2A (0.38) | PLA2G2ATHRATHRBKDM4EKMT2A | |
| SCHEMBL5235591 | 0.88 | L3MBTL1 (0.39) | PLA2G2ATHRATHRBKMT2AMKNK2 | |
| SCHEMBL5232009 | 0.87 | PLA2G2A (0.38) | PLA2G2ATHRATHRBALDH1A1GAA | |
| SCHEMBL5234123 | 0.84 | ESR1 (0.38) | PLA2G2AKDM4EKMT2AMKNK2ALDH1A1 | |
| SCHEMBL5240015 | 0.83 | PDE5A (0.35) | THRATHRBALDH1A1HSD17B10DPP4 | |
| SCHEMBL5232392 | 0.83 | THRB (0.36) | PLA2G2ATHRATHRBKDM4EKMT2A | |
| SCHEMBL6703529 | 0.82 | DPP4 (0.35) | THRATHRBKDM4EKMT2ADPP4 | |
| SCHEMBL5233361 | 0.82 | ALDH1A1 (0.46) | PLA2G2ATHRATHRBKDM4EKMT2A | |
| SCHEMBL5233243 | 0.82 | PLA2G2A (0.38) | PLA2G2ATHRATHRBKMT2AALDH1A1 | |
| SCHEMBL5238788 | 0.81 | THRA (0.38) | PLA2G2ATHRATHRBPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | PLA2G2A 3137/4885THRA 1886/4885THRB 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.